Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study - Vijiaratnam, Nirosen; Girges, Christine; Auld, Grace; Chau, Marisa; Maclagan, Kate; King, Alexa; Skene, Simon; Chowdhury, Kashfia; Hibbert, Steve; Morris, Huw; Limousin, Patricia; Athauda, Dilan; et al. (BMJ open, 2021)
Keywords: Diabetes; Dopamine; Double-blind studies; Dyskinesia; GLP-1 receptor agonists; Laboratories; Movement disorders; Neurology; Parkinson's disease; Patients; Performance evaluation; Public health; Qualitative research; Questionnaires; Society